sever
chronic
viral
infect
hiv
hepat
c
viru
highli
preval
seriou
health
risk
adapt
anim
virus
human
host
recent
exemplifi
influenza
virus
sever
acut
respiratori
syndrom
coronaviru
also
continu
threat
high
demand
therefor
new
antivir
lead
compound
novel
therapeut
concept
review
origin
therapeut
concept
suppress
envelop
virus
present
base
specif
interact
carbohydratebind
agent
cba
glycan
present
viralenvelop
glycoprotein
approach
may
also
extend
pathogen
includ
parasit
bacteria
fungi
attempt
develop
effici
vaccin
chronic
virus
hiv
human
hepat
c
viru
hcv
far
fail
mainli
due
invent
immunolog
escap
mechan
virus
well
lack
effici
longterm
protect
vaccin
direct
conserv
epitop
virus
involv
acut
infect
influenza
viru
instead
broad
rang
chemotherapeut
agent
avail
treatment
variou
viral
infect
particular
hiv
howev
appear
longterm
side
effect
particular
eventu
emerg
viral
resist
drug
pressur
often
weaken
therapi
make
drug
useless
even
harm
long
run
target
current
avail
antivir
agent
essenti
virusencod
enzym
virusspecif
structur
protein
cellular
protein
viral
receptor
sometimesabund
presenc
glycan
viralenvelop
glycoprotein
never
serious
envisag
therapeut
target
glycan
viral
envelop
often
crucial
role
enabl
effici
transmiss
pathogen
andor
entri
suscept
target
cell
moreov
shown
presenc
glycan
envelop
virus
hiv
hcv
also
crucial
import
evas
immunolog
surveil
host
agent
interact
viralenvelop
glycan
may
therefor
compromis
effici
entri
viru
suscept
target
cell
agent
interfer
glycosyl
enzym
cell
rather
act
directli
bind
intact
glycan
viral
envelop
perhap
importantli
carbohydratebind
agent
cba
may
forc
viru
delet
least
part
glycan
shield
escap
drug
pressur
might
result
initi
immun
respons
uncov
immunogen
envelop
epitop
cba
may
becom
first
chemotherapeut
dual
mechan
antivir
action
first
direct
antivir
activ
bind
glycan
viral
envelop
subsequ
block
viru
entri
second
indirect
addit
antivir
action
result
progress
creation
delet
envelop
glycan
shield
therebi
trigger
immun
system
act
previous
hidden
immunogen
epitop
viral
envelop
fig
broader
perspect
apart
virus
pathogen
mycobacterium
tuberculosi
helicobact
pylori
parasit
may
also
suscept
novel
therapeut
approach
review
focu
cba
molecular
mechan
antivir
activ
fig
escap
mechan
hiv
respons
cba
pressur
escap
mechan
might
involv
immun
system
combat
viral
infect
also
discuss
interfer
cba
dendrit
cell
dc
specif
intercellular
adhes
molecul
grab
nonintegrin
dcsign
direct
captur
transmiss
hiv
pathogen
also
highlight
uniqu
featur
cba
therapeut
concept
potenti
pitfal
discuss
mannosebind
lectin
mbl
superfamili
strictli
mannosespecif
lectin
consist
subunit
similar
sequenc
overal
threedimension
structur
glycosyl
highli
divers
coand
posttransl
proteinmodif
reaction
broadli
divid
two
categori
olink
nlink
glycosyl
olink
glycosyl
probabl
occur
golgi
apparatu
carbohydr
moieti
coval
link
hydroxyl
oxygen
serin
threonin
also
bound
tyrosin
oglycosyl
variou
function
provid
ligand
selectin
resist
proteolysi
stem
region
membran
protein
creat
specif
recognit
phenomena
also
help
mask
immunogen
epitop
protein
olink
glycosyl
usual
nacetylgalactosamin
galnac
bind
sugar
also
involv
sugar
fucos
glucos
nacetylglucosamin
glcnac
galactos
andor
sialic
acid
also
often
found
oglycan
coval
nlink
glycan
fig
ad
cotransl
nativ
polypeptid
endoplasm
reticulum
er
block
fourteen
sugar
glc
man
glcnac
glycan
subject
extens
modif
transport
er
golgi
complex
reach
final
destin
insid
outsid
cell
er
earli
secretori
pathway
oligosaccharid
repertoir
still
small
golgi
complex
howev
glycan
acquir
complex
highli
divers
structur
termin
glycosyl
result
tremend
heterogen
divers
differ
cell
type
tissu
speci
help
increas
microheterogen
presenc
ident
genet
polypeptid
background
result
creation
new
function
specif
nglycan
may
also
import
role
proper
protein
fold
degrad
solubl
avoid
precipit
caus
lipophyl
aminoacid
stretch
nascent
polypeptid
also
control
proper
peptid
oligomer
sort
peptid
well
peptid
transport
traffick
act
univers
tag
specif
cellular
lectin
modifi
enzym
presenc
glycan
shield
peptid
also
enabl
effici
protect
glycoprotein
degrad
proteas
interact
carbohydr
cellular
lectin
also
crucial
import
effici
oper
innat
immun
system
exampl
includ
mannosebind
lectin
mbl
dcsign
defensin
macrophag
mannos
receptor
leukocyt
interact
endotheli
cell
repres
wellcharacter
exampl
celladhes
event
depend
glycanreceptor
interact
cellsurfac
glycoprotein
therefor
mediat
cell
adhes
signal
event
well
intercellular
commun
well
mammalian
cell
mani
differ
pathogen
includ
virus
bacteria
fungi
parasit
also
use
glycoprotein
extens
divers
function
part
similar
eukaryot
cell
howev
glycan
pathogen
particular
viralderiv
glycoprotein
produc
cellular
machineri
often
recogn
self
immun
system
therefor
glycan
pathogen
glycoprotein
viral
envelop
bacteri
cell
wall
help
escap
recognit
immun
system
subsequ
destruct
neutral
pathogen
class
carbohydratebind
agent
arbitrarili
two
differ
categori
cba
distinguish
lectin
protein
specif
recogn
carbohydr
glycan
structur
nonpeptid
smallsiz
agent
may
good
often
specif
affin
monosaccharid
andor
oligosaccharid
structur
exposur
cba
viru
cell
cultur
also
shown
forc
viru
delet
part
protect
glycan
shield
present
envelop
glycoprotein
assum
glycan
delet
trigger
enhanc
neutral
antibodi
respons
previous
hidden
immunogen
epitop
possibl
also
cellular
immun
respons
part
c
reproduc
permiss
ref
univers
amsterdam
chemokin
receptor
lymphocyt
functionassoci
antigen
c
syncytium
multinucl
giant
cell
form
follow
fusion
infect
cell
express
hivencod
envelop
glycoprotein
uninfect
cell
express
coreceptor
result
syncytium
subsequ
undergo
apoptosi
tabl
wellstudi
cba
undoubtedli
cyanovirinn
cvn
protein
compos
amino
acid
consist
two
sequenc
repeat
origin
purifi
extract
cyanobacterium
nostoc
ellipsosporum
elucid
cvn
crystal
structur
reveal
exist
domainswap
dimer
two
primari
carbohydratebind
site
two
secondari
carbohydratebind
site
opposit
end
dimer
carbohydraterecognit
site
bind
geometri
highmannos
glycan
particular
link
mannos
oligom
monomer
protein
isol
unicellular
freshwat
bloomform
cyanobacterium
microcysti
viridi
strain
microcysti
viridi
lectin
mvl
also
shown
compos
two
tandemli
repeat
homolog
domain
specif
possibl
mannos
oligom
smallest
target
man
glcnac
tetrasaccharid
core
scytovirin
svn
peptid
amino
acid
recent
isol
cyanobacterium
scytonema
varium
shown
pronounc
affin
mannos
trisaccharid
unit
cvn
svn
inhibit
hiv
infect
cell
cultur
effect
concentr
nm
respect
mvl
howev
less
inhibitori
hiv
cba
deriv
sea
coral
gerardia
savaglia
gsa
one
first
lectin
isol
primit
eukaryot
organ
dmannosespecif
cba
dimer
monom
kda
requir
calcium
preserv
full
carbohydratebind
activ
actinohivin
deriv
actinomycet
longisporum
alba
protein
amino
acid
griffithsin
grft
isol
red
alga
griffithsin
spp
protein
amino
acid
also
recent
shown
recogn
mannosetyp
glycan
interestingli
calciumindepend
grft
dimer
protein
four
mannos
carbohydratebind
domain
cbd
separ
short
linker
sequenc
homolog
primari
aminoacid
sequenc
found
far
gsa
show
complet
suppress
infect
cell
line
concentr
concentr
syncytia
format
infect
jurkat
cell
block
actinohivin
inhibit
tcell
macrophag
infect
nm
concentr
cell
cultur
grft
exquisit
activ
cxcchemokin
receptor
tropic
ccchemokin
receptor
tropic
isol
ec
rang
nm
cba
broad
array
carbohydr
specif
includ
mannos
glucos
galactos
fucos
sialic
acid
glcnac
galnac
oligom
preval
mani
plant
famili
monom
dimer
form
plant
lectin
predomin
trimer
tetram
even
octam
plant
lectin
exist
lead
quaternari
protein
complex
rel
high
molecular
weight
overview
see
ref
crystal
structur
number
plant
lectin
complex
carbohydr
oligom
determin
mannosespecif
lectin
galanthu
nivali
gna
exampl
structur
composit
highmannosetyp
nglycan
triantennari
complextyp
nglycan
b
hybridtyp
nglycan
c
highmannosetyp
nglycan
abundantli
present
envelop
glycoprotein
hiv
rare
mammalian
glycoprotein
besid
highmannosetyp
nglycan
complextyp
hybridtyp
nglycan
also
present
asn
asparagin
fuc
fucos
gal
galactos
glcnac
nacetylglucosamin
man
mannos
sa
sialic
acid
ser
serin
thr
threonin
x
amino
acid
except
prolin
cba
also
isol
invertebr
cvl
chaetopteru
variapedatu
mermaid
laxu
oneistu
wherea
cvl
specif
mermaid
calciumdepend
mannosespecif
cba
interestingli
mermaid
report
strong
structur
resembl
mammalian
dcsign
antivir
activ
cvl
hiv
rang
antihiv
activ
mermaid
yet
report
mammalian
also
sever
type
cba
mbl
calciumdepend
multimer
cba
found
serum
contain
subunit
approxim
kda
besid
mannos
also
bind
glcnac
fucos
mbl
part
innat
immun
system
bind
pathogen
initi
step
lectin
pathway
order
opson
pathogen
dcsign
anoth
exampl
vertebr
mannosespecif
lectin
predominantli
present
immatur
dc
function
dc
recognit
uptak
pathogen
hiv
lead
antigen
present
cell
variou
cba
apart
mbl
dcsign
also
part
innat
andor
adapt
immun
system
mammalian
defensin
cyclic
famili
solubl
glycanbind
protein
probabl
beststudi
lectin
immun
system
galectin
also
role
cellcel
recognit
trigger
intracellular
signal
cascad
lead
apoptosi
final
monoclon
antibodi
one
broadli
neutral
antihiv
antibodi
direct
epitop
hiv
envelop
glycoprotein
lie
around
region
epitop
contain
highmannosetyp
glycan
present
sever
highli
conserv
nglycosyl
site
specif
predomin
interact
site
probabl
termin
mannos
oligom
highmannos
glycan
note
howev
specif
recogn
hiv
glycan
specif
interact
peptid
moieti
near
glycan
structur
ref
antibodi
found
inhibitori
iii
b
differ
cell
type
ec
per
ml
howev
note
activ
vari
depend
natur
subtyp
isol
evalu
cours
screen
new
antibiot
activ
fungi
actinomycet
strain
actinomadura
hibisca
found
produc
pradimicin
prma
antibiot
uniqu
nonpeptid
structur
contain
amino
acid
dala
carbohydr
dxylos
attach
substitut
naphtacenequinon
fig
prma
bind
termin
dmannos
pyranosid
calcium
yield
ternari
complex
consist
two
molecul
prma
four
molecul
mannos
one
calcium
atom
benanomicin
bnma
fig
close
relat
antibiot
mannos
specif
similar
prma
also
isol
actinomycet
actinomadura
spadix
studi
antifung
activ
prma
bnma
semisynthet
analogu
compound
antibiot
formal
known
welldefin
carbohydratebind
properti
antivir
activ
cell
cultur
report
effect
concentr
rank
lower
micromolar
rang
sever
research
group
focu
synthesi
character
synthet
cba
bind
specif
oligosaccharid
structur
binuclear
copper
ii
complex
acycl
pyridineand
pyrimidinebas
compound
tetrapyrrol
porfyrin
deriv
report
carbohydratebind
properti
compound
may
potenti
benefit
antivir
diagnost
agent
howev
smallsiz
cba
antivir
data
avail
potenti
cytotox
care
address
far
would
interest
therefor
explor
antivir
properti
compound
identifi
novel
synthet
lowmolecularweight
cba
lead
compound
chemotherapeut
potenti
broad
rang
protein
bind
highmannosetyp
glycan
hiv
sever
bind
mode
distinguish
one
group
lectin
interact
ctype
lectin
via
calcium
ion
two
bestknown
exampl
calciumdepend
carbohydratebind
lectin
innat
immun
system
dcsign
serum
liver
mbl
anoth
group
lectin
interact
singletermin
carbohydr
intim
interact
multipl
sugar
ring
without
need
metal
ion
third
group
lectin
interact
yet
resolv
carbohydr
specif
mbl
broad
mbl
recogn
dmannos
glcnac
lfucos
common
motif
among
sugar
defin
figur
lowsiz
nonpeptid
carbohydratebind
antigen
cba
structur
formula
calciumdepend
mannosebind
pradimicin
benanomicin
b
antibiot
cba
produc
actinomadura
hibiscu
actinomadura
spadix
respect
red
repres
dalanin
moieti
black
repres
dihydrobenzonaphtacenequinon
core
green
repres
carbohydr
part
molecul
anoth
exampl
ctype
lectin
dcsign
crystal
complex
man
glcnac
ref
protein
data
bank
pdb
id
fig
interestingli
intern
mannos
man
link
core
carbohydr
bind
princip
calcium
site
equatori
hydroxyl
coordin
calcium
ion
form
hydrogen
bond
amino
acid
coordin
calcium
uda
exampl
calciumindepend
cba
bound
glcnac
molecul
sandwich
bind
site
highaffin
cbd
first
uda
molecul
lowaffin
cbd
second
uda
molecul
highaffin
cbd
form
residu
lowaffin
calcium
shown
green
sphere
wherea
carbohydr
shown
yellow
stick
represent
calcium
coordin
shown
detail
hydrogen
bond
import
coordin
residu
shown
dot
sphere
gray
sphere
repres
calcium
site
anoth
carbohydraterecognit
domain
c
hydrogen
bond
van
der
waal
interact
aromat
ring
stack
glcnac
glcnacspecif
lectin
urtica
dioica
uda
pdb
id
two
isolectin
vi
molecul
shown
blue
green
dot
line
hydrogenbond
contact
uda
glcnac
sugar
residu
label
b
c
nonreduc
end
hydrogenbond
pattern
van
der
waal
contact
narcissu
psuedonarcissu
lectin
carbohydratebind
domain
complex
cbd
form
residu
import
sugar
recognit
multipl
hydrogen
bond
van
der
waal
interact
aromaticr
stack
glcnac
two
uda
molecul
pdb
id
fig
inde
least
five
hydrogen
bond
form
carbohydratelectin
complex
well
sever
ring
stack
individu
glcnac
entiti
residu
uda
molecul
molecular
interact
narcissu
pseudonarcissu
lectin
also
reveal
pdb
id
fig
narcissu
psuedonarcissu
lectin
isolectin
contain
three
cbd
one
monom
cbd
seem
equal
affin
particular
carbohydr
equal
occupi
addit
three
conserv
cbd
uniqu
fourth
lowaffin
carbohydratebind
site
observ
near
tryptophan
cluster
three
residu
creat
polar
patch
cbd
pocket
restrict
carbohyd
ligand
axial
hydroxyl
group
multialign
variou
monocot
mannosebind
lectin
reveal
strike
sequenc
ident
among
narcissu
pneudonarcissu
agglutinin
npa
narcissu
hybrid
cultivar
agglutinin
nha
galanthu
nivali
agglutinin
gna
lycori
radiata
agglutinin
lra
lycori
aurea
agglutinin
laa
zephyranthu
grandiflora
agglutinin
zga
contain
three
mannosebind
site
repres
conserv
qxdxnxvxi
motif
motif
bind
mannos
network
four
hydrogen
bond
interconnect
hydroxyl
mannos
four
qdni
aminoacid
residu
valin
present
within
motif
also
interact
mannos
van
der
waal
interact
interestingli
also
describ
npa
fourth
mannosebind
site
found
laa
near
tryptophan
cluster
investig
complex
molecular
interact
cba
carbohydr
ligand
enabl
ration
design
smallsiz
molecul
includ
peptidomimet
obviou
lowmolecularweight
cba
necess
fewer
interact
individu
carbohydr
glycan
thu
may
display
lower
affin
toward
carbohydr
oligom
howev
nonpeptid
smallsiz
antibiot
prma
bnma
fig
shown
affin
specif
mannos
oligom
suffici
high
enabl
effici
antivir
activ
unfortun
crystal
structur
yet
obtain
prma
allow
visual
molecular
interact
antibiot
target
mannos
glycan
inform
becam
avail
optim
cba
may
possibl
numer
studi
shown
cba
prevent
hiv
infect
cell
cultur
shown
mani
viru
strain
includ
laboratori
strain
member
group
differ
clade
infect
mani
differ
target
cell
includ
laboratori
cell
line
peripheralblood
mononuclear
cell
pbmc
macrophag
dc
inhibit
hiv
infect
cba
occur
effect
concentr
rank
lower
nanomolar
micromolar
rang
antivir
activ
also
depend
natur
cba
viru
strain
investig
although
studi
perform
laboratori
viru
strain
adapt
growth
immort
cell
line
cem
molt
sever
studi
shown
pronounc
activ
cba
differ
viru
clade
isol
pbmc
cultur
strain
bal
primari
macrophag
cell
cultur
size
cba
carbohydr
specif
seem
import
role
eventu
potenc
antivir
efficaci
gener
wherea
mannosespecif
cba
inhibitori
hiv
uda
exampl
glcnacspecif
lectin
poor
antihiv
activ
report
lectin
carbohydr
specif
interestingli
cba
assum
welldefin
glycan
specif
may
still
differ
consider
antivir
potenc
although
phenomenon
well
understood
clear
howev
subtl
differ
threedimension
conform
well
proper
steric
avail
glycan
effici
interact
cba
presenc
lack
welldefin
glycan
conform
viral
envelop
import
role
eventu
antivir
efficaci
cba
format
syncyti
giant
cell
cell
persist
infect
uninfect
cell
also
effici
prevent
cba
inhibit
giantcel
format
noninfect
tcell
cocultur
usual
requir
cba
concentr
five
tenfold
higher
need
inhibit
cellfre
viru
infect
target
cell
cba
nonpeptid
prma
howev
equal
effect
inhibitori
potenti
mode
viral
transmiss
recent
shown
cba
inhibit
infect
dc
dcdirect
transfer
also
demonstr
cba
pronounc
inhibitori
effect
viru
captur
cell
express
dcsign
subsequ
transmiss
viru
uninfect
cell
dcsign
natur
ctype
lectin
pivot
role
innat
immun
defenc
fig
elimin
pathogen
infect
host
dcsign
captur
pathogen
hiv
envelop
glycan
subsequ
present
pathogen
pathogen
fragment
appropri
cell
observ
potenti
import
microbicid
viewpoint
microbicid
aim
prevent
viru
infect
may
occur
exposur
individu
viru
sexual
intercours
inde
dcsignmedi
viru
captur
transmiss
cell
believ
among
first
event
occur
viral
infect
process
sexual
contact
box
howev
exact
role
hiv
transmiss
remain
controversi
boggiano
et
al
wang
et
al
agent
effici
prevent
first
step
viru
propag
may
qualifi
promis
microbicid
agent
potenti
prevent
persist
establish
infect
observ
cba
might
compet
directli
dcsign
captur
hiv
deserv
investig
term
impact
effici
viru
captur
subsequ
transmiss
viru
cell
interestingli
recent
report
langerin
ctype
lectin
present
epitheli
langerhan
cell
lc
prevent
transmiss
lc
intern
captur
hiv
particl
subsequ
intracellular
degrad
although
mechan
may
effici
firstlin
inactiv
hiv
cbaexpos
hiv
strain
may
decreas
effici
lc
elimin
hiv
time
may
compromis
abil
viru
effici
transmit
dc
interact
sever
cba
extens
investig
includ
prokaryot
cvn
actinohivin
varieti
plant
lectin
includ
hippeastrum
hybrid
agglutinin
hha
uda
nonpeptid
lowmolecularweight
antibiot
prma
monoclon
antibodi
hivenvelop
andor
sever
glycan
structur
interestingli
delet
nglycan
aminoacid
posit
andor
render
monoclon
antibodi
complet
incap
effici
neutral
viru
particl
asparagin
posit
previous
shown
crystallograph
complex
indispens
effici
interact
monoclon
antibodi
interact
monoclon
antibodi
glycan
welldefin
epitop
also
reveal
sever
studi
alter
glycosyl
pattern
hiv
er
inhibit
glycosidas
ii
prevent
proper
fold
consequ
interact
er
lectin
calnexin
inhibit
result
fewer
infecti
viru
particl
releas
drugtreat
cell
addit
viru
particl
glycan
strip
becam
markedli
less
infecti
interestingli
combin
cba
mannosidas
inhibitor
dmj
led
express
synergist
antivir
activ
exposur
glycandelet
mutant
strain
dmj
result
enhanc
suppress
mutant
virusinduc
cytopath
cell
cultur
therefor
presenc
intact
glycan
shield
also
proven
indispens
optim
infect
effici
interact
hiv
target
cell
studi
determin
direct
interact
cba
fix
molecul
reveal
strong
bind
affin
cvn
hha
prma
actinohivin
howev
certain
cba
cvn
hha
low
dissoci
rate
observ
result
indic
cba
exert
strong
virtual
irrevers
bind
agreement
cellular
experi
show
short
preincub
cellfre
viru
particl
cba
infect
cell
markedli
increas
antivir
activ
cba
bind
cba
prevent
initi
viruscel
interact
inde
found
presenc
cba
viru
could
still
effici
bind
cell
howev
one
next
step
entri
process
bind
coreceptor
andor
subsequ
exposur
targetcel
membran
becom
block
presenc
cba
exact
molecular
mechan
blockad
viru
entri
andor
fusion
yet
determin
howev
assum
attach
cba
glycan
hinder
prevent
conform
chang
flexibl
requir
properli
interact
cellmembran
receptor
fusion
process
number
case
even
observ
bind
viru
particl
target
cell
enhanc
presenc
cba
phenomenon
may
indic
sort
crosslink
viru
particl
cellmembran
glycoprotein
occur
altern
cbainduc
conform
chang
may
allow
optim
interact
site
cellular
receptor
mention
site
contain
nglycan
delet
nglycan
vicin
site
simian
immunodefici
viru
strain
report
increas
bind
effici
mutant
conclud
pathogen
bind
dcsign
dendrit
cell
dc
specif
intercellular
adhes
molecul
grab
nonintegrin
caus
longlast
chronic
infect
often
induc
toler
immun
evas
dcsign
ctype
calciumdepend
lectin
predominantli
express
dc
also
extent
macrophag
activ
b
cell
lymphoid
tissu
skin
dermi
placenta
intestin
genit
mucosa
function
tetram
consist
cytoplasm
domain
transmembran
domain
exogen
hepta
repeat
domain
allow
multimer
termin
carbohydr
highmannos
recognit
domain
dc
present
site
pathogen
entri
exampl
mucos
barrier
underneath
vagin
epithelia
recogn
trap
pathogen
activ
dc
migrat
drain
lymph
node
naiv
cell
prime
erad
pathogen
fig
one
role
dcsign
grab
present
cell
enabl
close
contact
allow
antigen
present
cell
dc
effici
captur
particl
ctype
lectin
dcsign
receptor
follow
dc
contact
cell
viru
particl
observ
cellcel
junction
possibl
creat
infecti
synaps
passag
virion
two
cell
type
facilit
synaps
depend
dcsign
express
strong
cellcel
adhes
mediat
lymphocyt
functionassoci
antigen
interact
shown
case
hiv
infecti
synaps
lead
effici
transfer
pathogen
cell
certain
glycan
might
particularli
import
shield
site
antibodi
recognit
exposur
hiv
antivir
drug
eventu
result
appear
phenotyp
resist
cell
cultur
hivinfect
individu
antivir
drug
resist
usual
due
aminoacid
mutat
andor
delet
viral
target
particular
drug
directli
indirectli
interact
mani
case
one
aminoacid
chang
suffici
provok
mark
degre
drug
resist
although
sometim
sever
mutat
requir
pronounc
phenotyp
resist
becom
evid
viral
fit
infect
often
compromis
presenc
resist
mutat
howev
compensatori
mutat
may
also
occur
aminoacid
mutat
contribut
drug
resist
rather
meant
restor
fit
viru
hiv
exposur
cba
invari
result
appear
accumul
aminoacid
mutat
predominantli
put
nglycosyl
motif
ref
either
asparagin
serin
threonin
mutat
lead
annihil
glycosyl
site
glycan
delet
observ
howev
glycoprotein
mutant
viru
strain
consist
approxim
highmannosetyp
glycan
approxim
glycan
b
fig
preferenti
site
glycan
delet
occur
cba
pressur
fig
inde
highmannosetyp
glycan
site
affect
prolong
cba
pressur
interestingli
phenomenon
consist
occur
regardless
natur
cba
observ
presenc
manspecif
cvn
prma
andor
manspecif
plant
lectin
hha
gna
glcnacspecif
plant
lectin
uda
nglycanrecogn
monoclon
antibodi
ref
close
correl
number
glycan
delet
envelop
particular
hiv
strain
degre
phenotyp
drug
resist
gener
greater
number
glycan
delet
hiv
greater
degre
cba
resist
howev
first
glycosylationsit
delet
occur
cba
pressur
hivinfect
cell
cultur
phenotyp
resist
rare
observ
exampl
mutant
viru
strain
isol
contain
least
three
glycosylationsit
mutat
without
appear
visibl
phenotyp
resist
glcnacspecif
uda
therefor
seem
threshold
number
glycan
delet
signific
phenotyp
cba
resist
evid
far
mani
mutant
strain
contain
nine
glycan
delet
isol
escal
cba
pressur
mutant
viru
strain
less
sensit
cba
interestingli
sever
mutant
viru
strain
less
infect
result
lower
viral
fit
compar
wildtyp
viru
howev
case
mutant
viru
strain
isol
contain
glycan
delet
yet
increas
infect
fit
unclear
structur
requir
mutant
must
fulfil
increas
infect
howev
viru
strain
never
observ
emerg
five
glycan
concomitantli
affect
fact
among
fifti
independ
mutant
viru
isol
emerg
cba
pressur
three
demonstr
increas
infect
much
evid
indic
glycan
shield
prevent
immun
system
effici
neutral
viru
strain
lack
highli
conserv
nlink
glycan
posit
design
fig
owe
differ
number
amino
acid
within
loop
highli
sensit
neutral
bolmstedt
cowork
also
show
glycosyl
aminoacid
posit
shield
neutral
antibodi
kang
colleagu
recent
report
hiv
envencod
protein
delet
glycan
domain
surround
bind
site
variabl
loop
expos
immunogen
epitop
much
higher
level
wildtyp
viru
may
provid
tool
novel
vaccin
immunogen
specif
nlink
glycosyl
modif
envelop
domain
siv
sivhiv
hybrid
variant
also
shown
evolv
host
alter
recognit
neutral
antibodi
studi
highli
resist
neutral
polyclon
antisera
monoclon
antibodi
shown
elimin
nglycan
attach
site
envelop
result
dramat
increas
sensit
neutral
monoclon
antibodi
importantli
remov
specif
nglycan
led
increas
sensit
neutral
antibodi
recogn
epitop
within
outsid
sequenc
inde
mutat
result
increas
antibodi
recognit
epitop
also
redirect
antibodi
respons
loop
distant
linear
polypeptid
sequenc
rhesu
monkey
infect
mutant
siv
strain
lack
combin
two
nglycosyl
site
mark
increas
antibodi
bind
specif
peptid
deriv
glycandelet
region
observ
result
increas
neutral
activ
result
convincingli
demonstr
presenc
nglycan
limit
neutral
antibodi
respons
siv
help
shield
viru
immun
recognit
result
also
illustr
delet
two
glycosyl
site
viral
env
gene
suffici
trigger
signific
neutral
antibodi
respons
blay
et
al
show
signific
diverg
env
protein
occur
time
macaqu
infect
siv
strain
contain
hiv
env
subtyp
b
siv
background
importantli
total
number
potenti
nglycosyl
site
increas
time
remark
degre
conserv
pattern
chang
env
glycan
find
suggest
configur
glycan
shield
consider
constraint
agreement
find
poon
et
al
show
neg
exclus
interact
occur
often
coloc
glycan
wherea
posit
inclus
interact
restrict
distant
glycan
data
impli
adapt
repertoir
altern
configur
glycan
shield
limit
function
interact
nglycan
therefor
seem
like
cba
exposur
siv
hiv
strain
would
serious
compromis
constraint
forc
aid
acquir
immunodefici
syndrom
dcsign
dendriticcellspecif
intercellular
adhes
molecul
nonintegrin
hcv
human
hepat
c
viru
lsign
liverlymph
nodesign
sar
sever
acut
respiratori
syndrom
viru
progress
delet
envelop
glycan
allow
immun
system
becom
activ
involv
inhibit
viru
infect
conclus
much
data
current
avail
show
glycan
delet
viral
envelop
uncov
immunogen
epitop
result
increas
neutral
mutant
viru
pathogen
suscept
cba
therapi
shown
dcsign
recogn
intern
numer
virus
bacteria
protozoa
addit
hiv
tabl
way
dcsign
consid
univers
pathogen
receptor
inde
recent
identif
carbohydr
specif
sign
molecul
highmannoseandor
fucosecontain
glycan
led
identif
variou
pathogen
recogn
receptor
tabl
dcsign
bind
intern
dengu
viru
human
cytomegaloviru
hcv
ebola
viru
allow
effici
tran
infect
target
cell
also
well
document
hcv
close
interact
dcsign
liverlymph
node
l
sign
close
homologu
dcsign
express
special
liver
lymphnod
endotheli
cell
antigenpres
capac
captur
hcv
signposit
cell
highli
glycosyl
highmannos
type
envelop
glycoprotein
facilit
hcv
transmiss
proxim
hepatocyt
dcsign
lsign
also
shown
enhanc
infect
mediat
marburg
viru
glycoprotein
gp
protein
sever
acut
respiratori
syndrom
coronaviru
sarscov
phdepend
endocytosi
might
promot
viru
dissemin
although
tuberculosi
primarili
infect
macrophag
also
bind
dc
interact
cellwal
compon
manlam
mannosyl
lipoarabinomannan
dcsign
bind
manlam
dcsign
dc
block
dc
matur
induc
express
immunosuppress
result
tuberculosi
enabl
suppress
immun
activ
signal
allow
immun
escap
probiot
bacteria
lactobacillu
spp
also
exert
immun
suppress
dcsign
induct
regulatori
cell
recent
shown
serotyp
streptococcu
pneumonia
specif
interact
dcsign
capsular
polysaccharid
immunolog
consequ
unclear
h
pylori
parasit
protozoa
schistosoma
mansoni
shown
bind
dcsign
nonsialyl
lewi
antigen
express
lipopolysaccharid
bacterium
cellwal
glycolipid
parasit
respect
result
immun
regul
advantag
pathogen
leishmania
mexicana
also
shown
express
glycoconjug
recogn
dcsign
clear
oftenindispens
interact
variou
pathogen
dcsign
requir
allow
effici
pathogen
transmiss
eventu
target
cell
andor
immun
escap
success
persist
host
therefor
like
cba
bind
pathogen
glycoconjug
directli
compet
lectin
innat
immun
system
cba
may
prevent
effici
captur
transmiss
pathogen
andor
suppress
effici
immun
respons
pathogen
therefor
predict
cba
may
gener
role
abrog
success
pathogen
infect
persist
cba
therefor
put
broader
microbi
therapeut
context
explor
sole
hiv
therapi
uniqu
featur
cba
concept
unambigu
shown
cba
effici
inhibit
viru
entri
inhibit
fusion
cellfre
hiv
particl
suscept
cell
form
syncytia
persist
infect
uninfect
cell
cba
also
prevent
captur
viru
particl
dcsign
subsequ
transmiss
viru
cell
cba
treatment
virusinfect
cell
provok
drug
pressur
viru
result
predomin
delet
nglycan
hiv
envelop
glycan
delet
uncov
previous
hidden
immunogen
epitop
may
give
immun
system
opportun
produc
humor
andor
cellular
respons
fig
uniqu
featur
cba
concept
differenti
therapeut
approach
current
avail
box
direct
interact
carbohydratebind
agent
cba
glycan
viral
envelop
glycoprotein
cba
pressur
forc
hiv
delet
nglycan
envelop
glycoprotein
multipl
cba
bind
one
envelop
target
molecul
high
genet
barrier
crossresist
cbaresist
mutant
viru
strain
antivir
alter
interact
mutant
glycandelet
virus
target
cell
cbainduc
glycan
delet
compromis
protect
role
intact
glycan
shield
hiv
eventu
antivir
cba
activ
may
combin
direct
drugmedi
viru
suppress
indirect
delay
induct
specif
antivir
immun
respons
mutant
envelop
cba
concept
may
also
appli
chronic
envelop
viru
infect
human
hepat
c
viru
pathogen
dendriticcellspecif
intercellular
adhes
molecul
nonintegrin
dcsign
recogn
bacteria
fungi
parasit
may
also
suscept
cba
approach
contrast
exist
drug
treatment
hiv
interact
specif
aminoacid
configur
target
protein
cba
directli
interact
glycan
present
envelop
hiv
import
realiz
cba
need
taken
virusinfect
cell
order
exert
antivir
activ
interfer
synthesi
glycan
glycoprotein
per
se
respect
concept
differ
entir
inhibitor
cellular
glycosyl
dmj
castanospermin
aim
disturb
glycan
format
viral
glycoprotein
time
may
also
disturb
format
glycan
cellular
glycoprotein
cba
pressur
progress
forc
viru
delet
nglycan
mutat
pattern
uniqu
consist
occur
presenc
antihiv
drug
known
antivir
rel
high
number
nglycan
present
molecul
approxim
glycan
depend
natur
viru
clade
individu
viru
strain
reason
assum
multipl
individu
cba
simultan
bind
everi
molecul
contrast
inhibitor
cba
stoichiometr
bind
target
one
drug
molecul
interact
one
target
protein
molecul
multipl
bind
cba
singl
molecul
result
cba
high
genet
barrier
mean
sever
mutat
owe
glycan
delet
need
accumul
signific
phenotyp
drug
resist
becom
evid
tradit
current
drug
appear
singl
mutat
least
two
three
mutat
target
protein
usual
suffici
produc
signific
drop
sensit
viru
particular
drug
cba
select
target
nglycan
cbamut
viru
strain
like
show
crossresist
drug
act
target
proteas
integras
revers
transcriptas
except
rule
may
drug
target
transmembran
inde
preliminari
find
indic
mutant
viru
strain
contain
variou
nglycan
delet
show
diminish
sensit
fusion
inhibitor
enfuvirtid
also
known
fuzeon
remain
seen
howev
whether
consist
behaviour
mutant
viru
strain
whether
particular
glycandelet
viru
strain
intrins
low
sensit
enfuvirtid
unrel
absenc
nglycan
certain
glycan
may
instrument
role
correct
fold
protein
immedi
nativ
peptid
form
ribosom
er
therefor
expect
correct
fold
becom
hamper
glycan
lack
viral
envelop
aminoacid
mutat
glycosyl
motif
compromis
alter
fold
may
affect
effici
interact
mutat
envelop
coreceptor
molecul
viru
fusion
efficaci
eventu
fit
mutant
viru
strain
transmiss
hiv
believ
mediat
carbohydraterecogn
dcsignexpress
cell
immatur
dc
present
vaginaluterin
mucosaepitheli
border
assum
mode
interact
cell
mutat
glycandefici
hiv
particl
alter
owe
chang
glycan
landscap
envelop
protect
role
glycan
shield
hide
immunogen
epitop
immun
system
may
get
lost
least
compromis
delet
particular
glycan
glycan
delet
may
trigger
product
neutral
antibodi
specif
peptid
epitop
previous
shield
glycan
whether
phenomenon
occur
cbatreat
individu
remain
determin
seem
like
also
current
unknown
strong
effici
neutral
antibodi
respons
mutant
viru
strain
emerg
cba
pressur
whether
viru
use
immunolog
subvers
circumv
cba
drug
pressur
would
also
interest
see
whether
extent
cellular
immun
respons
would
trigger
condit
contribut
provok
cellular
immun
respons
might
make
eventu
inhibit
viru
infect
cbatreat
individu
none
exist
antivir
chemotherapeut
shown
potenti
act
concert
immun
system
increas
therapeut
pressur
mutat
viru
therefor
treatment
hiv
cba
may
becom
first
strategi
combin
drugmedi
viru
suppress
induct
specif
antivir
immunolog
respons
phenomenon
may
result
selfvaccin
cbaexpos
hivinfect
individu
mean
chemotherapeut
agent
principl
combin
concert
action
chemotherapi
immun
respons
prove
valid
may
also
appli
chronic
infect
virus
highli
glycosyl
envelop
hcv
also
acut
viru
infect
exampl
influenza
viru
sarscov
ebola
viru
may
highli
sensit
inhibitori
action
cba
shown
certain
cba
felin
human
coronavirus
cvn
ebola
viru
cell
cultur
besid
virus
pathogen
dcsignrecogn
tuberculosi
h
pylori
fungi
contain
glycanrich
cell
wall
aspergillu
spp
cryptococcu
spp
candida
spp
even
parasit
may
becom
ideal
candid
microorgan
explor
suscept
inhibitori
action
cba
therefor
potenti
cba
select
target
envelop
virus
may
also
extend
pathogen
entir
differ
natur
glycan
pathogen
suffici
differ
host
accept
therapeut
window
may
achiev
consid
cba
larger
context
beyond
therapeut
field
viru
infect
may
reveal
unpreced
therapeut
potenti
trigger
extens
effort
chemist
microbiologist
explor
novel
therapeut
avenu
broadest
possibl
sens
potenti
pitfal
cba
concept
virtual
known
cba
inhibitori
hiv
infect
except
lowmolecularweight
nonpeptid
antibiot
prma
bmna
analogu
fig
protein
agent
expens
produc
scaleup
purifi
may
also
storag
stabil
problem
although
plant
lectin
remark
temperatureand
phstabl
bioavail
also
expect
low
peptid
cba
therefor
pharmacokinet
pharmacodynam
could
unfavour
particularli
chronic
therapeut
administr
besid
sometim
pronounc
mitogen
redbloodcellagglutin
activ
lectin
might
also
endow
inflammatori
activ
cellular
toxic
also
lectin
cvn
capac
stimul
variou
differenti
marker
human
leukocyt
antigen
hladr
must
emphas
although
properti
unfavour
undesir
therapeut
viewpoint
number
intens
biolog
side
effect
highli
depend
natur
cba
exampl
wherea
cvn
shown
display
broad
varieti
side
effect
cba
gna
hha
show
much
fewer
side
effect
moreov
side
effect
observ
cvn
shown
independ
carbohydratebind
properti
therefor
proper
select
cba
high
select
viral
glycan
minim
cellular
side
effect
must
achiev
goal
given
proteinac
natur
lectin
could
assum
repeat
system
administr
cba
eventu
elicit
specif
antibodi
respons
reaction
immun
system
may
hamper
attenu
activ
cba
viral
carbohydr
make
less
antivir
activ
may
also
provok
hyperreact
immun
system
would
necessit
prematur
abrog
continu
administr
cba
obvious
lowmolecularweight
nonpeptid
cba
suffer
potenti
drawback
greatest
concern
protein
nonpeptid
cba
degre
select
may
eventu
show
viral
glycoprotein
potenti
discrimin
pathogen
nonself
glycoprotein
cellular
self
glycoprotein
howev
hiv
envelop
carri
higher
proport
highmannosetyp
glycan
mammalian
glycoprotein
threedimension
configur
glycan
display
glycoprotein
pathogen
shown
import
may
help
cba
distinguish
nonself
glycan
pathogen
self
glycan
host
highmannosetyp
glycan
contain
termin
mannos
oligom
rare
glycan
mammalian
glycoprotein
fact
mbl
dcsign
distinguish
pathogenderiv
glycoprotein
cellular
glycoprotein
enabl
select
elimin
pathogen
specif
interact
carbohydr
configur
also
import
cba
discrimin
glycan
present
commens
bacteria
glycan
must
target
viralenvelop
glycoprotein
challeng
goal
one
believ
achiev
discov
design
cba
show
mark
degre
discrimin
select
pathogen
glycan
glycan
host
includ
glycan
commens
bacteria
although
cba
protein
prokaryot
plantlectin
cba
demonstr
smallsiz
nonpeptid
cba
molecular
weight
less
kda
fig
effici
suppress
viral
fungal
infect
make
class
compound
feasibl
realist
tool
pathogen
inhibit
clinic
set
howev
much
work
still
done
synthet
lowmolecularweight
compound
need
design
discov
enabl
effici
explor
novel
function
class
antivir
way
enabl
care
ration
select
cba
high
specif
select
pathogen
side
effect
host
especi
includ
longterm
treatment
modal
sever
synthet
cba
lead
compound
alreadi
avail
trigger
synthesi
structur
relat
compound
organ
medicin
chemist
allow
extens
structureact
relationship
studi
investig
could
indic
cba
like
potent
select
candid
preclin
investig
glycan
envelop
cell
wall
pathogen
often
seem
similar
function
role
escap
recognit
immun
system
recognit
lectin
innat
immun
system
allow
effici
transmiss
pathogen
concept
interf
andor
abrog
protect
mechan
therefor
put
broader
context
sole
antivir
therapeut
intervent
mani
differ
microorgan
virus
certain
bacteria
fungi
yeast
parasit
thoroughli
investig
potenti
interact
cba
howev
care
taken
ensur
microorgan
pivot
role
maintain
homeostasi
human
function
nonpathogen
lactobacilli
vagin
environ
commens
bacteria
intestin
neg
affect
cba
includ
bacteri
strain
screen
cba
may
allow
select
highestposs
pathogenselect
specif
cba
earli
stage
drug
develop
cba
consid
valuabl
agent
right
directli
suppress
prevent
pathogen
infect
host
fig
howev
forc
pathogen
mutat
delet
protect
glycan
shield
escap
cba
pressur
add
excit
new
dimens
cba
novel
conceptu
class
antimicrobi
agent
may
inde
repres
first
agent
combin
direct
chemotherapeut
activ
indirect
activ
involv
immun
system
trigger
humor
respons
produc
neutral
antibodi
andor
cellular
respons
tcellbas
immun
although
trigger
cellular
immun
respons
cba
still
confirm
vivo
indirect
inform
suggest
immun
respons
expect
prolong
treatment
pathogen
cba
